Celltrion starts Phase I and Phase III clinical trials for Humira biosimilar
Celltrion recently announced that they made a clinical trial application for ‘CT-P17,’ a biosimilar referencing the rheumatoid arthritis therapy ‘Humira(generic name: adalimumab),’ to the U.K. Medicines and Healthcare Products Regulatory Agency(MHRA).
Celltrion said they would start a Phase I cl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
